Stephen Vernon Frye

US Patent:

6541503, Apr 1, 2003

Filed:

Aug 8, 2001

Appl. No.:

09/924431

Inventors:

Stephen Thomas Davis - Durham NC
Scott Howard Dickerson - Chapel Hill NC
Stephen Vernon Frye - Durham NC
Philip Anthony Harris - Raleigh NC
Lee Frederick Kuyper - Durham NC
Karen Elizabeth Lackey - Hillsborough NC
Michael Joseph Luzzio - Groton CT
James Marvin Veal - Apex NC
Duncan Herrick Walker - Summit NJ

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 31429

US Classification:

514414, 514419, 514426, 548452, 548483, 548484, 5462771, 5462781, 544111

Abstract:

Compounds of formula (I): wherein X is N, CH, CCF , or C(C aliphatic); R is sulfonic acid, C aliphatic-sulfonyl, sulfonyl-C aliphatic, C aliphatic-sulfonyl-C aliphatic, C aliphatic-amino, R -sulfonyl, R sulfonyl-C aliphatic, R -aminosulfonyl, R -aminosulfonyl-C aliphatic, R -sulfonylamino, R -sulfonylamino-C aliphatic, aminosulfonylamino, di-C aliphatic amino, di-C aliphatic aminocarbonyl, di-C aliphatic aminosulfonyl, di-C aliphatic amino, di-C aliphatic aminocarbonyl, di-C aliphatic aminosulfonyl-C aliphatic, (R ) -Arylamino, (R ) -Arylsulfonyl, (R ) -Aryl-aminosulfonyl, (R ) -Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R is hydrogen; and further wherein R and R are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.

US Patent:

7105529, Sep 12, 2006

Filed:

Nov 30, 2001

Appl. No.:

09/999331

Inventors:

Stephen Thomas Davis - Durham NC, US
Scott Howard Dickerson - Chapel Hill NC, US
Stephen Vernon Frye - Durham NC, US
Philip Anthony Harris - Raleigh NC, US
Lee Frederick Kuyper - Durham NC, US
Karen Elizabeth Lackey - Hillsborough NC, US
Michael Joseph Luzzio - Groton CT, US
James Marvin Veal - Apex NC, US
Duncan Herrick Walker - Summit NJ, US

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 31/505
A61K 31/44
A61K 31/425

US Classification:

514272, 291365, 291366

Abstract:

Compounds of formula (I): wherein X is N, CH, CCF, or C(Caliphatic); Ris sulfonic acid, Caliphatic-sulfonyl, sulfonyl-Caliphatic, Caliphatic-sulfonyl-Caliphatic, Caliphatic-amino, R-sulfonyl, Rsulfonyl-Caliphatic, R-aminosulfonyl, R-aminosulfonyl-Caliphatic, R-sulfonylamino, R-sulfonylamino-Caliphatic, aminosulfonylamino, di-Caliphatic amino, di-Caliphatic aminocarbonyl, di-Caliphatic aminosulfonyl, di-Caliphatic amino, di-Caliphatic aminocarbonyl, di-Caliphatic aminosulfonyl-Caliphatic, (R)-Arylamino, (R)-Arylsulfonyl, (R)-Aryl-aminosulfonyl, (R)-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, Ris hydrogen; and further wherein Rand Rare optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.

US Patent:

20130059836, Mar 7, 2013

Filed:

May 12, 2011

Appl. No.:

13/641729

Inventors:

Xiaodong Wang - Chapel Hill NC, US
Jing Liu - Carrboro NC, US
Chao Yang - Franklin Park NJ, US
Weihe Zhaug - Chapel Hill NC, US
Stephen Frye - Chapel Hill NC, US
Dmitri Kireev - Chapel Hill NC, US

International Classification:

C07D 487/04
A61P 35/02
A61K 31/551
A61P 35/00
A61K 31/519
A61K 31/5377

US Classification:

51421021, 5142621, 544262, 51425216, 5142345, 544122, 514218, 540575

Abstract:

Compound of Formula (I): are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof in the treatment of cancer.

US Patent:

20130137679, May 30, 2013

Filed:

Jul 1, 2011

Appl. No.:

13/807347

Inventors:

Jian Jin - Chapel Hill NC, US
Bryan Roth - Durham NC, US
Stephen Frye - Chapel Hill NC, US

International Classification:

C07D 403/12
A61K 31/551
A61K 31/4725
C07D 417/12
C07D 405/14
A61K 31/55
A61K 31/538
A61K 31/4965
A61K 45/00
A61K 31/454
C07D 471/04
C07D 413/14
C07D 241/04
C07D 401/12
A61K 31/496
C07D 217/22
C07D 403/02

US Classification:

514218, 5142305, 51425304, 51425402, 51425406, 51425503, 514309, 514322, 540575, 544121, 544362, 544368, 544371, 544400, 546141, 546199

Abstract:

The present invention relates to novel functionally selective ligands of dopamine D2 receptors, FIG. including agonists, antagonists, and inverse agonists. The invention further relates to the use of these compounds for treating central nervous system disorders related to D2 receptors.

US Patent:

51927578, Mar 9, 1993

Filed:

Dec 20, 1990

Appl. No.:

7/631129

Inventors:

Michael R. Johnson - Chapel Hill NC
Stephen V. Frye - Durham NC

Assignee:

Glaxo Inc. - Research Triangle Park NC

International Classification:

A61K 31555
C07D48722

US Classification:

514185

Abstract:

Cobalt prophyrins of the following formula (l): ##STR1## or a salt or ligand complex thereof and their synthesis, pharmaceutical compositions and use in controlling obesity.

US Patent:

59771267, Nov 2, 1999

Filed:

May 14, 1998

Appl. No.:

9/079002

Inventors:

Kenneth William Batchelor - Durham NC
Stephen Vernon Frye - Durham NC

Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC

International Classification:

A61K 31435

US Classification:

514284

Abstract:

The present invention relates to methods for preparing and using compounds of formula (I), wherein carbons 1 and 2 are joined by either a single or a double bond; R. sup. 1 is hydrogen or methyl; R. sup. 2 is hydrogen or methyl; R. sup. 3 is (A) wherein X, W, Z, R. sup. 4, and R. sup. 5, are various groups, and pharmaceutically acceptable solvates thereof and their use in the treatment of androgen responsive and mediated diseases.

US Patent:

54570980, Oct 10, 1995

Filed:

Jan 28, 1994

Appl. No.:

8/189020

Inventors:

Stephen V. Frye - Durham NC
David Middlemiss - Ware, GB
Francis G. Fang - Durham NC

Assignee:

Glaxo Inc. - Research Triangle Park NC

International Classification:

A61K 31435

US Classification:

514211

Abstract:

There are disclosed preparation and compounds of formula (I): ##STR1## wherein R. sup. 1 and R. sup. 2 are hydrogen or lower alkyl or taken together are a --CH. sub. 2 -- group to form a cyclopropane ring. X is ##STR2## wherein R. sup. 5, R. sup. 6, R. sup. 7, and R. sup. 8 are hydrogen or alkyl, p and q are independently either 0 or 1; R. sup. 3 is alkyl, alkenyl, cycloalkyl, alkoxy, thiopyridyl, adamantyl, --NR. sup. 9 R. sup. 10 or --Ar--NR. sup. 9 R. sup. 10 wherein R. sup. 9 and R. sup. 10 are hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, adamantyl, aryl, benzyl, diphenylmethyl, norbornyl, or taken together with the nitrogen to form 4 to 8 atom heterocyclic group, ##STR3## optionally substituted with alkyl groups; Ar is aromatic R. sup. 4 is hydrogen or methyl; Z is --O--, --NH--, --N(lower alkyl), --S--, --SO--, --SO. sub. 2 --, --CH. sub. 2 CH. sub.

US Patent:

58178180, Oct 6, 1998

Filed:

Mar 14, 1996

Appl. No.:

8/617859

Inventors:

Kenneth William Batchelor - Durham NC
Stephen Vernon Frye - Durham NC

Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC

International Classification:

A61K 3158

US Classification:

546 77

Abstract:

The present invention relates to compounds of formula (I), wherein carbons 1 and 2 are joined by either a single or a double bond; R. sup. 1 is hydrogen or methyl; R. sup. 2 is hydrogen or methyl; R. sup. 3 is (A) or (B) wherein X, W, Z, R. sup. 4, R. sup. 5, R. sup. 6, R. sup. 7 and R. sup. 8 are various groups, and pharmaceutically acceptable solvates thereof and their use in the treatment of androgen responsive and mediated diseases. ##STR1##.